News NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough | Neurodegenerative Diagnostic Antibodies June 10, 2026 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Completes Ph 1a Clinical Study on OLX-07010Next →Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients
